Correspondence to editorial on "Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis".
作者信息
Kim Hayeon, Park Min Jeong, Kim Myeong Gyu, Kim Kyungim
机构信息
College of Pharmacy, Korea University, Sejong, Korea.
Division of Endocrinology & Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
出版信息
Clin Mol Hepatol. 2024 Oct;30(4):989-991. doi: 10.3350/cmh.2024.0705. Epub 2024 Aug 27.
Abstract
摘要
相似文献
1
Correspondence to editorial on "Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis".致关于“胰高血糖素样肽-1受体激动剂与噻唑烷二酮类药物治疗非酒精性脂肪性肝病的比较：网状Meta分析”的社论的信函。
Clin Mol Hepatol. 2024 Oct;30(4):989-991. doi: 10.3350/cmh.2024.0705. Epub 2024 Aug 27.
2
Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis.比较胰高血糖素样肽-1 受体激动剂和噻唑烷二酮类药物治疗非酒精性脂肪性肝病的疗效：一项网状荟萃分析。
Clin Mol Hepatol. 2023 Jul;29(3):693-704. doi: 10.3350/cmh.2022.0330. Epub 2023 Mar 9.
3
Reply to correspondence on "Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis".对关于“胰高血糖素样肽-1受体激动剂与噻唑烷二酮类药物治疗非酒精性脂肪性肝病的比较：网状Meta分析”的通信的回复
Clin Mol Hepatol. 2024 Oct;30(4):1039-1041. doi: 10.3350/cmh.2024.0801. Epub 2024 Sep 24.
4
Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on "Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis".基于肠促胰岛素的疗法在代谢功能障碍相关脂肪性肝病（MASLD）管理中的应用：拼图中的一块：关于“胰高血糖素样肽-1受体激动剂与噻唑烷二酮类药物治疗非酒精性脂肪性肝病的比较：网状Meta分析”的社论
Clin Mol Hepatol. 2024 Oct;30(4):649-652. doi: 10.3350/cmh.2024.0558. Epub 2024 Jul 23.
5
Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂与噻唑烷二酮类药物治疗非酒精性脂肪性肝病的比较：一项网状荟萃分析。
Acta Diabetol. 2022 Apr;59(4):519-533. doi: 10.1007/s00592-021-01830-7. Epub 2022 Jan 6.
6
Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials.胰高血糖素样肽1（GLP-1）受体激动剂、吡格列酮和维生素E对非酒精性脂肪性肝病患者肝脏组织学的比较疗效：随机对照试验的系统评价和试点网状Meta分析
Expert Rev Gastroenterol Hepatol. 2023 Mar;17(3):273-282. doi: 10.1080/17474124.2023.2172397. Epub 2023 Feb 6.
7
Animal studies on glucagon-like peptide-1 receptor agonists and related polyagonists in nonalcoholic fatty liver disease.关于胰高血糖素样肽-1 受体激动剂和相关多激动剂在非酒精性脂肪性肝病中的动物研究。
Hormones (Athens). 2024 Dec;23(4):611-619. doi: 10.1007/s42000-024-00541-2. Epub 2024 Mar 12.
8
Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety.2型糖尿病患者非酒精性脂肪性肝病的治疗：疗效与安全性综述
Ther Adv Endocrinol Metab. 2018 Jan;9(1):15-28. doi: 10.1177/2042018817741852. Epub 2017 Dec 7.
9
Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials.用于治疗非酒精性脂肪性肝病和非酒精性脂肪性肝炎的胰高血糖素样肽-1受体激动剂：随机对照试验的最新荟萃分析
Metabolites. 2021 Jan 27;11(2):73. doi: 10.3390/metabo11020073.
10
Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病合并非酒精性脂肪性肝病的 Meta 分析。
Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021.
引用本文的文献
1
Reply to correspondence on "Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis".对关于“胰高血糖素样肽-1受体激动剂与噻唑烷二酮类药物治疗非酒精性脂肪性肝病的比较：网状Meta分析”的通信的回复
Clin Mol Hepatol. 2024 Oct;30(4):1039-1041. doi: 10.3350/cmh.2024.0801. Epub 2024 Sep 24.
本文引用的文献
1
Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on "Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis".基于肠促胰岛素的疗法在代谢功能障碍相关脂肪性肝病（MASLD）管理中的应用：拼图中的一块：关于“胰高血糖素样肽-1受体激动剂与噻唑烷二酮类药物治疗非酒精性脂肪性肝病的比较：网状Meta分析”的社论
Clin Mol Hepatol. 2024 Oct;30(4):649-652. doi: 10.3350/cmh.2024.0558. Epub 2024 Jul 23.
2
Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity.非肥胖型非酒精性脂肪性肝病与内脏型肥胖、肌肉减少症和肌内脂肪变性的相关性。
Clin Mol Hepatol. 2023 Oct;29(4):987-1001. doi: 10.3350/cmh.2023.0035. Epub 2023 Jul 5.
3
Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis.比较胰高血糖素样肽-1 受体激动剂和噻唑烷二酮类药物治疗非酒精性脂肪性肝病的疗效：一项网状荟萃分析。
Clin Mol Hepatol. 2023 Jul;29(3):693-704. doi: 10.3350/cmh.2022.0330. Epub 2023 Mar 9.
4
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future.非酒精性脂肪性肝病肝脂肪变的无创性影像学生物标志物：现状与未来。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S123-S135. doi: 10.3350/cmh.2022.0357. Epub 2022 Dec 12.
5
Comparison between obese and non-obese nonalcoholic fatty liver disease.肥胖与非肥胖非酒精性脂肪性肝病的比较。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S58-S67. doi: 10.3350/cmh.2022.0350. Epub 2022 Dec 5.
6
Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease.2 型糖尿病会增加肥胖和非酒精性脂肪性肝病患者发生肝纤维化的风险。
Obesity (Silver Spring). 2021 Nov;29(11):1950-1960. doi: 10.1002/oby.23263. Epub 2021 Sep 23.
7
Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: A meta-analysis of randomized controlled trials.胰高血糖素样肽-1受体激动剂对瘦素和抵抗素循环水平的影响：一项随机对照试验的荟萃分析。
Diabetes Res Clin Pract. 2021 Jul;177:108899. doi: 10.1016/j.diabres.2021.108899. Epub 2021 Jun 5.
8
Magnetic Resonance Spectroscopy of Hepatic Fat from Fundamental to Clinical Applications.从基础到临床应用的肝脏脂肪磁共振波谱分析
Diagnostics (Basel). 2021 May 7;11(5):842. doi: 10.3390/diagnostics11050842.
9
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.一项安慰剂对照试验评估皮下司美格鲁肽在非酒精性脂肪性肝炎中的疗效。
N Engl J Med. 2021 Mar 25;384(12):1113-1124. doi: 10.1056/NEJMoa2028395. Epub 2020 Nov 13.
10
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.全球非肥胖或消瘦非酒精性脂肪性肝病的患病率、发病率和结局：系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2020 Aug;5(8):739-752. doi: 10.1016/S2468-1253(20)30077-7. Epub 2020 May 12.
Zotero 插件